Maintenance therapy for peptic ulcer disease
- 1 April 1991
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 5 (s1) , 37-47
- https://doi.org/10.1111/j.1365-2036.1991.tb00747.x
Abstract
SUMMARY: Peptic ulcers tend to recur; recurrence may be associated with an increased risk of potentially lethal complications, such as haemorrhage or perforation. Therapy aims to keep ulcers in remission. Currently, the optimal maintenance therapy is long‐term, continuous administration of antisecretory drugs. More than 80% of patients remain in remission during maintenance therapy. Maintenance therapy may be required for the life of the patient, but it is acceptable to patients and is safe.Keywords
This publication has 24 references indexed in Scilit:
- Long-term maintenance treatment of gastric ulcers with ranitidineAlimentary Pharmacology & Therapeutics, 2007
- Ranitidine maintenance treatment of non‐steroidal anti‐inflammatory drug‐induced duodenal ulcerationAlimentary Pharmacology & Therapeutics, 1989
- Six years of continuous cimetidine treatment in peptic ulcer disease: efficacy and safetyAlimentary Pharmacology & Therapeutics, 1988
- The cost‐effectiveness of maintenance therapy for duodenal ulceration with an H2‐antagonistAlimentary Pharmacology & Therapeutics, 1988
- Case 2: The Chronically Recurring UlcerScandinavian Journal of Gastroenterology, 1987
- Incompletely and completely healed duodenal ulcers' outcome in maintenance treatment: a double blind controlled study.Gut, 1985
- Natural History of Duodenal UlcerDigestive Diseases, 1985
- CIMETIDINE AND GASTRIC CANCERThe Lancet, 1979
- Gross Bleeding from the Digestive Tract:The frequency of manifest bleeding in peptic ulcer, with regard to the duration of the disease and to the age of the diseasedActa Medica Scandinavica, 1944